Elicio Therapeutics, Inc. Common Stock (ELTX)
Elicio Therapeutics, Inc. is a biotechnology company focused on developing immunotherapies that stimulate the body’s immune system to fight cancer. Their platform utilizes particulate vaccines designed to target and activate immune cells, aiming to improve the effectiveness of cancer treatments and address unmet medical needs in oncology.
Company News
Elicio Therapeutics announced successful results for its ELI-002 off-the-shelf cancer vaccine, which induced mKRAS-specific T cell responses in 99% of evaluable patients. The vaccine targets common KRAS mutations in solid tumors and showed promising survival outcomes in pancreatic and colorectal cancer patients.
Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating on the stock. Keefe, Bruyette & Woods analyst Michael Perito downgraded SoFi from a Market Perform rating to an Underperform rating and lowered the price target from $7.50 to $6.50, citing recent outperforman...